TODD STRATEGY GROUP

Lobbying for ASTRAZENECA PHARMACEUTICALS LP · â€‹Biopharmaceutical Company.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Delaware · House · Senate · $80,000.00 income · posted Oct 20, 2025

Lobbying activity 2

Medicare/Medicaid

340B Program. Home Infusion for Part B Products. Medicare Reimbursement for New Technologies.

Health Issues

General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.